Skip to main content
Tsubota Laboratory Incorporated logo

Tsubota Laboratory Incorporated — Investor Relations & Filings

Ticker · 4890 ISIN · JP3535700003 T Professional, scientific and technical activities
Filings indexed 41 across all filing types
Latest filing 2026-06-01 Share Issue/Capital Cha…
Country JP Japan
Listing T 4890

About Tsubota Laboratory Incorporated

https://tsubota-lab.com/en/

Tsubota Laboratory Incorporated is a research and development company that originated as a startup from Keio University. It is engaged in the creation of pharmaceuticals and medical devices. The company's primary focus is on ophthalmology, developing solutions for conditions such as myopia, dry eye, and presbyopia. Additionally, it explores treatments for central nervous system (CNS) disorders and brain diseases. The corporate strategy centers on out-licensing its developed pipelines to commercial partners. A notable pipeline is a therapeutic candidate designed to curtail the progression of myopia.

Recent filings

Filing Released Lang Actions
第三者割当による新株予約権(行使価額修正選択権付)の発行に関するお知らせ
Share Issue/Capital Change Classification · 97% confidence The document is a Japanese corporate announcement by Tsubo Lab (code 4890) detailing the third-party allotment issuance of its 8th, 9th, and 10th new share subscription rights (warrants) including terms, exercise price, and fundraising purpose. This is clearly a capital-raising event via issuance of equity instruments. Under our classification scheme, this corresponds to a Share Issue/Capital Change announcement (Code: SHA), as it notifies the market of a new share issue and changes in the company’s capital structure.
2026-06-01 Japanese
子会社の異動を伴う株式取得に関するお知らせ
Merger & Acquisition Classification · 90% confidence The document is a corporate disclosure by Tsubo Lab announcing the Board of Directors’ resolution to acquire 100% of the shares of Mediaroduce and make it a consolidated subsidiary. It details the background, terms of share acquisition, financials of the target company, related‐party considerations, and integration timeline. This is a definitive acquisition announcement, not an earnings release or financing notice. It falls under M&A transaction filings (share acquisition to create a subsidiary), matching the Merger & Acquisition category.
2026-06-01 Japanese
臨時報告書
M&A Activity Classification · 91% confidence The document is a Japanese "臨時報告書" filed under the Financial Instruments and Exchange Act, disclosing a board resolution to acquire shares of another company (株式会社メディプロデュース), thereby creating a subsidiary. This is a statutory announcement of an acquisition transaction, which falls under M&A Activity filings rather than an internal management change, earnings release, or other category.
2026-06-01 Japanese
臨時報告書
Regulatory Filings Classification · 85% confidence The document is a Japanese "臨時報告書" filed under the Financial Instruments and Exchange Act to notify a change in the company’s audit firm. It is not an annual or interim financial report, not an earnings announcement, nor a management or director change (the auditors are independent third parties). It is a mandatory regulatory disclosure of special corporate information. Under the given taxonomy, this falls into the generic “Regulatory Filings” category (RNS) as it is a statutory report filing that does not fit other specific categories.
2026-05-20 Japanese
会計監査人の異動に関するお知らせ
Regulatory Filings Classification · 90% confidence The document is a formal corporate press release announcing the change of the company’s external accounting auditor (公認会計士) effective at the upcoming annual general meeting. It does not contain actual audited financial statements (so it is not an Audit Report itself), nor is it detailing management or board member changes. It is a compliance/regulatory announcement notifying stakeholders of the auditor appointment and resignation. Therefore, it falls into the ‘Regulatory Filings’ fallback category.
2026-05-20 Japanese
第14 期定時株主総会の付議議案の決定に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a short public notice dated May 20, 2026, announcing that the board of directors has resolved the date, venue and agenda items for the 14th Annual General Meeting of shareholders. It does not include the actual proxy materials or detailed meeting presentations, nor substantive financial data. It is essentially a miscellaneous regulatory disclosure regarding the AGM, thus falling into the fallback category for general regulatory announcements.
2026-05-20 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.